Navigation system for Neurosurgery and Spine Operations including Disposables ישראל - עברית - Ministry of Health

navigation system for neurosurgery and spine operations including disposables

tzamal medical ltd - רופא - מערכת ניווט (כולל מתכלים) לניתוחים נוירוכירורגים ועמוד שידרה - לפי הוראות יצרן

impalnts+accessories for neurosurgical ישראל - עברית - Ministry of Health

impalnts+accessories for neurosurgical

צמל-יעקובסון בע'מ - רופא - משתלים + נלווים להידרוצפלוס

Implants, Instruments & Accessories for Surgery, Orthopedics & Spine and Neurosurgery ישראל - עברית - Ministry of Health

implants, instruments & accessories for surgery, orthopedics & spine and neurosurgery

tzamal medical ltd - רופא - משתלים, מכשור ואביזרים נלווים המשמשים בכירורגיה

Interventional Neuroradiology Devices ישראל - עברית - Ministry of Health

interventional neuroradiology devices

סלע מדיקל בע"מ - רופא - מגוון מוצרים המשמשים לצינתורי מוח כגון טיפול במפרצות, מלפורמצויות וטיפול בשבץ מוחי

NERVE STIMULATORS + NeuroNavigation System ישראל - עברית - Ministry of Health

nerve stimulators + neuronavigation system

בפקס בע"מ - מומחה - לשימוש בבתי חולים ואוניברסיטאות

אנפלייט 250 מקג ישראל - עברית - Ministry of Health

אנפלייט 250 מקג

amgen europe b.v. - romiplostim - אבקה להכנת תמיסה לזריקה - romiplostim 250 mcg/vial - romiplostim - romiplostim - nplate is indicated for the treatment of thrombocytopaenia in adult patients with chronic immune (idiopathic) thrombocytopaenic purpura (itp)- who are non-splenectomised and have had an inadequate response, or are intolerant, to both corticosteroids and immunoglobulins;-who are splenectomised and have had an inadequate response to splenectomy

מימפרה 30 מ"ג ישראל - עברית - Ministry of Health

מימפרה 30 מ"ג

amgen europe b.v. - cinacalcet hydrochloride 30 mg - film coated tablets - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. mimpara may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.

מימפרה 60 מ"ג ישראל - עברית - Ministry of Health

מימפרה 60 מ"ג

amgen europe b.v. - cinacalcet hydrochloride 60 mg - film coated tablets - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. mimpara may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.

מימפרה 90 מ"ג ישראל - עברית - Ministry of Health

מימפרה 90 מ"ג

amgen europe b.v. - cinacalcet hydrochloride 90 mg - film coated tablets - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. mimpara may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.

ניופוגן 30 MU בקבוקונים ישראל - עברית - Ministry of Health

ניופוגן 30 mu בקבוקונים

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu/ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).